Skip to main content
Erschienen in: Herz 6/2016

25.01.2016 | Kardiomyopathie | Review article

The MOGE(S) classification

A TNM-like classification for cardiomyopathies

verfasst von: E. Şahan, M.D., S. Şahan, M.D., M. Karamanlıoğlu, M.D., M. Gul, M.D., O. Tufekcioğlu, Assoc. Prof. M.D.

Erschienen in: Herz | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Cardiomyopathy is a disease of the heart muscle resulting from genetic defects, cardiac myocyte injury, or infiltration of the myocardium. Cardiomyopathies are traditionally defined as dilated, restrictive, and hypertrophic cardiomyopathy. Today, the genetic basis of most diseases has been clearly defined and has influenced the approach to familial diseases such as cardiomyopathies. Traditional definitions of cardiomyopathies, such as those by the American Heart Association and the European Society of Cardiology, do not consider the genetic basis of cardiomyopathies. In 2013, the World Heart Federation added the genetic basis of cardiomyopathies and proposed a descriptive genotype–phenotype nosology system termed “MOGE(S).” The MOGE(S) system resembles the TNM classification system for malignancy, and therefore it can be useful for the diagnosis, management, and treatment of cardiomyopathies in a similar manner to cancer management.
Literatur
1.
Zurück zum Zitat Maron BJ, Towbin JA, Thiene G et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816CrossRefPubMed Maron BJ, Towbin JA, Thiene G et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816CrossRefPubMed
2.
Zurück zum Zitat Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276CrossRefPubMed Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276CrossRefPubMed
3.
Zurück zum Zitat Arbustini E, Narula N, Dec WG et al (2013) The MOGE(S) classification for a phenotype–genotype nomenclature of cardiomyopathy. endorsed by the World Heart Federation. Glob Heart 8:355–382CrossRefPubMed Arbustini E, Narula N, Dec WG et al (2013) The MOGE(S) classification for a phenotype–genotype nomenclature of cardiomyopathy. endorsed by the World Heart Federation. Glob Heart 8:355–382CrossRefPubMed
4.
Zurück zum Zitat Blankerhorn MA, Gall EA (1956) Myocarditis and myocardosis: a clinicopathologic appraisal. Circulation 13:217–223CrossRef Blankerhorn MA, Gall EA (1956) Myocarditis and myocardosis: a clinicopathologic appraisal. Circulation 13:217–223CrossRef
5.
Zurück zum Zitat Bridgen W (1957) Uncommon myocardial diseases: the non-coronary cardiomyopathies. Lancet 273:1179–1184 Bridgen W (1957) Uncommon myocardial diseases: the non-coronary cardiomyopathies. Lancet 273:1179–1184
7.
Zurück zum Zitat Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 1980;44:672–3 Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 1980;44:672–3
8.
Zurück zum Zitat Sorajja P, Elliott PM, McKenna WJ (2000) The moleculargenetics of hypertrophic cardiomyopathy: prognostic implications. Europace 2:4–14CrossRefPubMed Sorajja P, Elliott PM, McKenna WJ (2000) The moleculargenetics of hypertrophic cardiomyopathy: prognostic implications. Europace 2:4–14CrossRefPubMed
9.
Zurück zum Zitat van Rijsingen IA, Arbustini E, Elliott PM et al (2012) Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 59:493–500CrossRefPubMed van Rijsingen IA, Arbustini E, Elliott PM et al (2012) Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 59:493–500CrossRefPubMed
10.
Zurück zum Zitat Ferlini A, Neri M, Gualandi F (2013) The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 23:4–14CrossRefPubMed Ferlini A, Neri M, Gualandi F (2013) The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 23:4–14CrossRefPubMed
11.
Zurück zum Zitat Corrado D, Basso C, Thiene G (2005) Is it time to include ion channel diseases among cardiomyopathies? J Electrocardiol 38(Suppl):81–87CrossRefPubMed Corrado D, Basso C, Thiene G (2005) Is it time to include ion channel diseases among cardiomyopathies? J Electrocardiol 38(Suppl):81–87CrossRefPubMed
12.
Zurück zum Zitat Pankuweit S, Richter A, Ruppert V, Maisch B (2009) Classification of cardiomyopathies and indication for endomyocardial biopsy revisited. Herz 34:55–62CrossRefPubMed Pankuweit S, Richter A, Ruppert V, Maisch B (2009) Classification of cardiomyopathies and indication for endomyocardial biopsy revisited. Herz 34:55–62CrossRefPubMed
13.
Zurück zum Zitat Webster G, Berul CI (2013) An update on channelopathies: from mechanisms to management. Circulation 127:126–140CrossRefPubMed Webster G, Berul CI (2013) An update on channelopathies: from mechanisms to management. Circulation 127:126–140CrossRefPubMed
14.
Zurück zum Zitat Diegoli M, Grasso M, Favalli V et al (2011) Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 58:925–934CrossRefPubMed Diegoli M, Grasso M, Favalli V et al (2011) Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 58:925–934CrossRefPubMed
15.
Zurück zum Zitat Pasotti M, Klersy C, Pilotto A et al (2008) Long-term outcome and risk stratificationin dilated cardiolaminopathies. J Am CollCardiol 52:1250–1260CrossRef Pasotti M, Klersy C, Pilotto A et al (2008) Long-term outcome and risk stratificationin dilated cardiolaminopathies. J Am CollCardiol 52:1250–1260CrossRef
16.
Zurück zum Zitat Claeys KG, van der Ven PF, Behin A et al (2009) Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. Acta Neuropathol 117:293–307CrossRefPubMed Claeys KG, van der Ven PF, Behin A et al (2009) Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. Acta Neuropathol 117:293–307CrossRefPubMed
17.
Zurück zum Zitat von Nandelstadh P, Soliymani R, Baumann M, Carpen O (2011) Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations. Biochem J 436:113–121CrossRef von Nandelstadh P, Soliymani R, Baumann M, Carpen O (2011) Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations. Biochem J 436:113–121CrossRef
18.
Zurück zum Zitat Ferlini A, Neri M, Gualandi F (2013) The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 23:4–14CrossRefPubMed Ferlini A, Neri M, Gualandi F (2013) The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 23:4–14CrossRefPubMed
19.
Zurück zum Zitat Clemen CS, Herrmann H, Strelkov SV, Schröder R (2013) Desminopathies: pathology and mechanisms. Acta Neuropathol 125:47–75CrossRefPubMed Clemen CS, Herrmann H, Strelkov SV, Schröder R (2013) Desminopathies: pathology and mechanisms. Acta Neuropathol 125:47–75CrossRefPubMed
20.
Zurück zum Zitat Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP (2012) Caveolinopathies. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (Eds) GeneReviews. University of Washington Seattle, Seattle Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP (2012) Caveolinopathies. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (Eds) GeneReviews. University of Washington Seattle, Seattle
21.
Zurück zum Zitat Lo HP, Cooper ST, Evesson FJ et al (2008) Limbgirdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 18:34–44CrossRefPubMed Lo HP, Cooper ST, Evesson FJ et al (2008) Limbgirdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 18:34–44CrossRefPubMed
22.
Zurück zum Zitat Walter MC, Reilich P, Thiele S et al (2013) Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8:26CrossRefPubMedPubMedCentral Walter MC, Reilich P, Thiele S et al (2013) Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 8:26CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ceravolo F, Messina S, Rodolico C et al (2014) D. Myoglobinuriaasfirst clinicalsignofa primary alphasarcoglycanopathy. Eur J Pediatr 173:239–242CrossRefPubMed Ceravolo F, Messina S, Rodolico C et al (2014) D. Myoglobinuriaasfirst clinicalsignofa primary alphasarcoglycanopathy. Eur J Pediatr 173:239–242CrossRefPubMed
24.
Zurück zum Zitat Hoffman EP, Clemens PR (1996) HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. Curr Opin Rheumatol 8:528–538CrossRefPubMed Hoffman EP, Clemens PR (1996) HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. Curr Opin Rheumatol 8:528–538CrossRefPubMed
25.
Zurück zum Zitat Wehnert MS, Bonne G (2002) The nuclear muscular dystrophies. Semin Pediatr Neurol 9:100–107CrossRefPubMed Wehnert MS, Bonne G (2002) The nuclear muscular dystrophies. Semin Pediatr Neurol 9:100–107CrossRefPubMed
Metadaten
Titel
The MOGE(S) classification
A TNM-like classification for cardiomyopathies
verfasst von
E. Şahan, M.D.
S. Şahan, M.D.
M. Karamanlıoğlu, M.D.
M. Gul, M.D.
O. Tufekcioğlu, Assoc. Prof. M.D.
Publikationsdatum
25.01.2016
Verlag
Springer Medizin
Schlagwort
Kardiomyopathie
Erschienen in
Herz / Ausgabe 6/2016
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-015-4394-0

Weitere Artikel der Ausgabe 6/2016

Herz 6/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.